POP Biotechnologies awarded $599,897 NIH contract for HIV vaccine development
POP Biotechnologies received a $599,897, two-year Phase I Small Business Innovation Research (SBIR) under Contract No. 75N93019C00011, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving, life-changing technology: a vaccine candidate against HIV commencing June 2019.
POP BIO’s light-activated nanoparticle drug delivery system, PhotoDOX, is an innovative cancer therapy designed to address solid tumors which resist current standards of care, such as cutaneous metastatic breast cancer (CMBC), liver cancer (hepatocellular carcinoma, HCC), and pancreatic cancer (PaCa).
PhotoDOX combines POP BIO’s porphyrin-phospholipid (PoP) liposome with the widely prescribed anti-cancer drug doxorubicin (Dox) to provide localized drug release with enhanced therapeutic benefit when activated by light.
PhotoDOX provides precise targeting of Dox to tumor sites in combination with a chemotherapy with the precision of light-based treatments.
The SNAP vaccine platform technology is a unique nanoparticle system that incorporates a revolutionary approach to vaccine development, functioning as a potent vaccine adjuvant.
The SNAP platform provides a unique binding mechanism enabling the efficient, rapid, and stable binding of one or more vaccine antigens to its surface, forming vaccine candidates with a markedly greater immune response compared to existing adjuvants.
Like a conventional vaccine adjuvant, the SNAP technology can be mixed with antigens just prior to vaccination-- making the SNAP approach a stockpileable strategy against emerging diseases, bioterrorism, or pandemics. Unlike typical vaccine adjuvants, the resulting antibody responses are orders of magnitude higher due to the stable, high-density antigen presentation to the immune system.